Nabriva Therapeutics plc

NasdaqCM:NBRV Stock Report

Mkt Cap: US$4.7m

Nabriva Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

J. Naftzger (55 yo)

1.33yrs

Tenure

Mr. J. Christopher Naftzger, Esquire, BA, JD, serves as General Counsel and Secretary of Nabriva Therapeutics plc since September 01, 2021 and serves as its Interim Chief Executive Officer since January 15...


Leadership Team

NamePositionTenureCompensationOwnership
Steven Gelone
President4.5yrsUS$1.54m0.47%
$ 22.4k
Colin Broom
Director5.33yrsUS$82.87k0.048%
$ 2.3k
Daniel Dolan
Chief Financial Officer1.83yrsUS$555.69k0%
$ 0
J. Naftzger
Interim CEO1.33yrsno data0.0091%
$ 434.1
Jodi VanDerveer
Senior VP & Head of Human Resources2yrsno datano data
Gary Sender
Consultant1.83yrsUS$1.03mno data
Christine Guico-Pabia
Chief Medical Officer1.25yrsno datano data

1.8yrs

Average Tenure

57yo

Average Age

Experienced Management: NBRV's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Steven Gelone
President1.83yrsUS$1.54m0.47%
$ 22.4k
Colin Broom
Director5.58yrsUS$82.87k0.048%
$ 2.3k
Daniel Burgess
Independent Chairman of the Board5.58yrsUS$132.59k0.014%
$ 643.0
Mark H. Corrigan
Independent Director1.58yrsUS$79.91k0.0094%
$ 446.4
Stephen Webster
Independent Director5.58yrsUS$112.00k0.015%
$ 710.0
Charles Rowland
Independent Director5.58yrsUS$103.48k0.020%
$ 947.0
Theodore Schroeder
Director4.42yrsUS$1.24m0.41%
$ 19.3k
Lisa Dalton
Independent Director1.58yrsUS$78.84k0.012%
$ 564.2
Carrie Bourdow
Independent Director5.58yrsUS$92.45k0.013%
$ 615.5

5.6yrs

Average Tenure

61yo

Average Age

Experienced Board: NBRV's board of directors are considered experienced (5.6 years average tenure).